Product Name :
Bivalirudin TFA
Description:
Bivalirudin TFA is a synthetic 20 residue peptide which reversibly inhibits thrombin. IC50 Value: Target: thrombin in vitro: Eptifibatide (8 mg/mL) added together with a low (70 ng/mL) concentration of bivalirudin (a direct thrombin inhibitor) effectively (approximately 90%) reduced platelet aggregation induced by thrombin (0.2 U/mL) . In thrombin generation assay (TGA), bivalirudin had no effect on these parameters up to 10 μmol/l . Bivalirudin-facilitated binding of MPO to BAEC resulted also in functional changes in terms of increased NO consumption as well as enhanced MPO-mediated redox modifications . in vivo: The use of bivalirudinprevented further increase in antiheparin/PF4 antibody IgG levels in rats . Three animals in the 500-mg/kg/24 h group, and 7 animals in the 2000-mg/kg/24 h group in the toxicokinetic assessment phase of the study were found dead or euthanized in extremis (following blood sampling). Plasma concentrations of bivalirudin appeared to be linear and dose independent . Clinical trial: Antithrombotic Effects of Ticagrelor Versus Clopidogrel . Phase 4
CAS:
1191386-55-6
Molecular Weight:
2294.31
Formula:
C100H139F3N24O35
Chemical Name:
(S)-4-((S)-2-((S)-2-(2-((S)-2-(2-(2-(2-(2-((S)-1-(D-phenylalanyl-L-prolyl-L-arginyl)pyrrolidine-2-carboxamido)acetamido)acetamido)acetamido)acetamido)-4-amino-4-oxobutanamido)acetamido)-3-carboxypropanamido)-3-phenylpropanamido)-5-(((S)-4-carboxy-1-(((2S, 3S)-1-((S)-2-(((S)-4-carboxy-1-(((S)-4-carboxy-1-(((S)-1-(((S)-1-carboxy-3-methylbutyl)amino)-3-(4-hydroxyphenyl)-1-oxopropan-2-yl)amino)-1-oxobutan-2-yl)amino)-1-oxobutan-2-yl)carbamoyl)pyrrolidin-1-yl)-3-methyl-1-oxopentan-2-yl)amino)-1-oxobutan-2-yl)amino)-5-oxopentanoic acid–2, 2, 2-trifluoroacetic acid (1/1)
Smiles :
CC(C)C[C@H](NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)CC1=CC=CC=C1)[C@@H](C)CC)C(O)=O.OC(=O)C(F)(F)F
InChiKey:
ZXZYMGVTLNJMKP-GRDNZSJBSA-N
InChi :
InChI=1S/C98H138N24O33.C2HF3O2/c1-5-52(4)82(96(153)122-39-15-23-70(122)92(149)114-60(30-34-79(134)135)85(142)111-59(29-33-78(132)133)86(143)116-64(43-55-24-26-56(123)27-25-55)89(146)118-67(97(154)155)40-51(2)3)119-87(144)61(31-35-80(136)137)112-84(141)58(28-32-77(130)131)113-88(145)63(42-54-18-10-7-11-19-54)117-90(147)66(45-81(138)139)110-76(129)50-107-83(140)65(44-71(100)124)109-75(128)49-106-73(126)47-104-72(125)46-105-74(127)48-108-91(148)68-21-13-38-121(68)95(152)62(20-12-36-103-98(101)102)115-93(150)69-22-14-37-120(69)94(151)57(99)41-53-16-8-6-9-17-53;3-2(4,5)1(6)7/h6-11,16-19,24-27,51-52,57-70,82,123H,5,12-15,20-23,28-50,99H2,1-4H3,(H2,100,124)(H,104,125)(H,105,127)(H,106,126)(H,107,140)(H,108,148)(H,109,128)(H,110,129)(H,111,142)(H,112,141)(H,113,145)(H,114,149)(H,115,150)(H,116,143)(H,117,147)(H,118,146)(H,119,144)(H,130,131)(H,132,133)(H,134,135)(H,136,137)(H,138,139)(H,154,155)(H4,101,102,103);(H,6,7)/t52-,57+,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,82-;/m0.{{Lycopene} MedChemExpress|{Lycopene} Immunology/Inflammation|{Lycopene} Technical Information|{Lycopene} In Vivo|{Lycopene} custom synthesis|{Lycopene} Autophagy} /s1
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
Bivalirudin TFA is a synthetic 20 residue peptide which reversibly inhibits thrombin. IC50 Value: Target: thrombin in vitro: Eptifibatide (8 mg/mL) added together with a low (70 ng/mL) concentration of bivalirudin (a direct thrombin inhibitor) effectively (approximately 90%) reduced platelet aggregation induced by thrombin (0.2 U/mL) . In thrombin generation assay (TGA), bivalirudin had no effect on these parameters up to 10 μmol/l . Bivalirudin-facilitated binding of MPO to BAEC resulted also in functional changes in terms of increased NO consumption as well as enhanced MPO-mediated redox modifications . in vivo: The use of bivalirudinprevented further increase in antiheparin/PF4 antibody IgG levels in rats . Three animals in the 500-mg/kg/24 h group, and 7 animals in the 2000-mg/kg/24 h group in the toxicokinetic assessment phase of the study were found dead or euthanized in extremis (following blood sampling). Plasma concentrations of bivalirudin appeared to be linear and dose independent . Clinical trial: Antithrombotic Effects of Ticagrelor Versus Clopidogrel . Phase 4|Product information|CAS Number: 1191386-55-6|Molecular Weight: 2294.31|Formula: C100H139F3N24O35|Chemical Name: (S)-4-((S)-2-((S)-2-(2-((S)-2-(2-(2-(2-(2-((S)-1-(D-phenylalanyl-L-prolyl-L-arginyl)pyrrolidine-2-carboxamido)acetamido)acetamido)acetamido)acetamido)-4-amino-4-oxobutanamido)acetamido)-3-carboxypropanamido)-3-phenylpropanamido)-5-(((S)-4-carboxy-1-(((2S, 3S)-1-((S)-2-(((S)-4-carboxy-1-(((S)-4-carboxy-1-(((S)-1-(((S)-1-carboxy-3-methylbutyl)amino)-3-(4-hydroxyphenyl)-1-oxopropan-2-yl)amino)-1-oxobutan-2-yl)amino)-1-oxobutan-2-yl)carbamoyl)pyrrolidin-1-yl)-3-methyl-1-oxopentan-2-yl)amino)-1-oxobutan-2-yl)amino)-5-oxopentanoic acid–2, 2, 2-trifluoroacetic acid (1/1)|Smiles: CC(C)C[C@H](NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)CC1=CC=CC=C1)[C@@H](C)CC)C(O)=O.{{Tegafur} medchemexpress|{Tegafur} Nucleoside Antimetabolite/Analog|{Tegafur} Technical Information|{Tegafur} Description|{Tegafur} manufacturer|{Tegafur} Epigenetic Reader Domain} OC(=O)C(F)(F)F|InChiKey: ZXZYMGVTLNJMKP-GRDNZSJBSA-N|InChi: InChI=1S/C98H138N24O33.PMID:34645436 C2HF3O2/c1-5-52(4)82(96(153)122-39-15-23-70(122)92(149)114-60(30-34-79(134)135)85(142)111-59(29-33-78(132)133)86(143)116-64(43-55-24-26-56(123)27-25-55)89(146)118-67(97(154)155)40-51(2)3)119-87(144)61(31-35-80(136)137)112-84(141)58(28-32-77(130)131)113-88(145)63(42-54-18-10-7-11-19-54)117-90(147)66(45-81(138)139)110-76(129)50-107-83(140)65(44-71(100)124)109-75(128)49-106-73(126)47-104-72(125)46-105-74(127)48-108-91(148)68-21-13-38-121(68)95(152)62(20-12-36-103-98(101)102)115-93(150)69-22-14-37-120(69)94(151)57(99)41-53-16-8-6-9-17-53;3-2(4,5)1(6)7/h6-11,16-19,24-27,51-52,57-70,82,123H,5,12-15,20-23,28-50,99H2,1-4H3,(H2,100,124)(H,104,125)(H,105,127)(H,106,126)(H,107,140)(H,108,148)(H,109,128)(H,110,129)(H,111,142)(H,112,141)(H,113,145)(H,114,149)(H,115,150)(H,116,143)(H,117,147)(H,118,146)(H,119,144)(H,130,131)(H,132,133)(H,134,135)(H,136,137)(H,138,139)(H,154,155)(H4,101,102,103);(H,6,7)/t52-,57+,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,82-;/m0./s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : ≥ 31 mg/mL (13.51 mM). H2O : 100 mg/mL (43.59 mM; Need ultrasonic).|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|Products are for research use only. Not for human use.|